110 related articles for article (PubMed ID: 26657125)
1. [Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLUĀ®)].
Kuriyama C; Ueta K; Arakawa K
Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):332-41. PubMed ID: 26657125
[No Abstract] [Full Text] [Related]
2. [Mode of SGLT inhibition by an SGLT2 inhibitor, canagliflozin and implication in renal and small intestinal effects].
Kuriyama C
Nihon Yakurigaku Zasshi; 2016; 148(5):245-252. PubMed ID: 27803437
[No Abstract] [Full Text] [Related]
3. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
Devineni D; Polidori D
Clin Pharmacokinet; 2015 Oct; 54(10):1027-41. PubMed ID: 26041408
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors: new reports.
Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
[TBL] [Abstract][Full Text] [Related]
5. Comparison chart of SGLT2 inhibitors.
Med Lett Drugs Ther; 2017 Jan; 59(1513):e26. PubMed ID: 28118654
[No Abstract] [Full Text] [Related]
6. [Pharmacological and clinical profile of a new SGLT2 inhibitor, luseogliflozin (LusefiĀ®)].
Takahashi T; Yamamoto K
Nihon Yakurigaku Zasshi; 2015 Sep; 146(3):150-8. PubMed ID: 26354015
[No Abstract] [Full Text] [Related]
7. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
8. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
Fortuna D; McCloskey LJ; Stickle DF
Clin Chim Acta; 2016 Jan; 452():138-41. PubMed ID: 26569347
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
10. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
11. Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update.
; Harper W; Clement M; Goldenberg R; Hanna A; Main A; Retnakaran R; Sherifali D; Woo V; Yale JF; Cheng AY;
Can J Diabetes; 2015 Aug; 39(4):250-2. PubMed ID: 26233723
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
13. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
14. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
16. Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
Nomiyama T
J Atheroscler Thromb; 2020 Nov; 27(11):1139-1140. PubMed ID: 32507831
[No Abstract] [Full Text] [Related]
17. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice.
Ji W; Zhao M; Wang M; Yan W; Liu Y; Ren S; Lu J; Wang B; Chen L
PLoS One; 2017; 12(6):e0179960. PubMed ID: 28665967
[TBL] [Abstract][Full Text] [Related]
18. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Washburn WN
J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
[No Abstract] [Full Text] [Related]
19. Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.
Ways K; Johnson MD; Mamidi RN; Proctor J; De Jonghe S; Louden C
Toxicol Pathol; 2015 Jan; 43(1):48-56. PubMed ID: 25398756
[TBL] [Abstract][Full Text] [Related]
20. Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.
Nat Rev Drug Discov; 2010 Mar; 9(3):182. PubMed ID: 20190779
[No Abstract] [Full Text] [Related]
[Next] [New Search]